查詢結果分析
相關文獻
- FDG PET-CT in Patients with Recurrent Thyroid Cancer with Elevated Serum Thyroglobulin But Negative Iodine-131 Whole Body Scan
- Discrepancy of Diagnostic and Post-Therapeutic Radioiodine Whole Body Scans in a Follicular Thyroid Carcinoma Patient with Multiple Bony Metastases
- 施打基因重組人類甲促素和停用甲狀腺素於碘-131清除速率及病人生活品質之比較
- 以側頸囊腫表徵之轉移性乳頭狀甲狀腺癌--二例報告
- Papillary and Follicular Thyroid Carcinomas with Bone Metastases: A Series of 39 Cases during a Period of 18 Years
- 甲狀腺癌切除後碘-131的清除治療
- 全身系統性惡性淋巴瘤合併甲狀腺淋巴瘤
- 輻射與甲狀腺癌
- 甲狀腺癌
- 人類甲狀腺癌由臨床至基礎醫學之研究
頁籤選單縮合
題名 | FDG PET-CT in Patients with Recurrent Thyroid Cancer with Elevated Serum Thyroglobulin But Negative Iodine-131 Whole Body Scan=氟-18-去氧葡萄糖正子電腦斷層掃描於甲狀腺球蛋白升高而碘-131掃描陰性之復發性甲狀腺癌病人的臨床應用 |
---|---|
作者 | 李佩瑛; 游冬齡; 許雅玲; 陳哲雄; 黃玉儀; 吳永衍; Lee, Pei-ing; You, Dong-ling; Hsu, Ya-ling; Chen, Jeffrey; Huang, Yu-yi; Wu, Yung-yen; |
期刊 | 核子醫學雜誌 |
出版日期 | 20071200 |
卷期 | 20:4 2007.12[民96.12] |
頁次 | 頁179-185 |
分類號 | 416.213 |
語文 | eng |
關鍵詞 | 甲狀腺癌; 氟-18-去氧葡萄糖正子電腦斷層掃描; 碘-131全身掃描; Thyroid cancer; 18F-FDG PET-CT; 131I whole body scan; |
中文摘要 | 背景:本回溯性研究的主要目的是評估氟-8-去氧葡萄糖正子電腦斷層掃描使用於甲狀腺球蛋白升高,但碘-131全身掃描結果陰性的甲狀腺癌病人之臨床應用。方法:從2003年8月至2006年11月,共有23位甲狀腺癌病人因爲疑似復發而至本院接受氟-18-去氧葡萄糖正子電腦斷層掃描。23位病人當中,男性佔14位,女性佔9位,年齡介於21-77歲,平均年齡爲53歲。所有病人均已接受甲狀腺全切除手術以及碘-131治療,但追蹤過程中發現甲狀腺球蛋白升高,而碘-131-全身掃描結果爲陰性。檢查當天,有8位病人的促甲狀腺激素大於30μIU/mL(高促甲狀腺激素),另外15位病人的促甲狀腺激素小於1μIU/mL(低促甲狀腺激素)。結果:本研究結果顯示17位病人之正子掃描結果爲陽性,其敏感度爲74%。17位病人當中,正子掃描總共發現25個病灶,其中包含:頸部14個、縱膈腔3個、肺4個、骨3個、骨周圍軟組織1個。另外,正子掃描結果也改變了8位病人的治療策略,其中6位病人接受頸部淋巴結摘除手術,1位病人接受頸部脊椎之放射線治療,1位病人接受頸部轉移性淋巴結之酒精注射治療。此研究中,有6位病人正子掃描結果爲陰性,其中3位病人於正子掃描後12個月內,被證實有頸部淋巴結轉移。本研究結果另外顯示高促甲狀腺激素並沒有提高正子掃描的敏感度。結論:本研究顯示,氟-18-去氧葡萄糖正子電腦斷層掃描能有效應用於復發性甲狀腺癌病人病灶的偵測。 |
英文摘要 | Background: The aim of this study is to evaluate the clinical role of 18F-FDG (FDG) PET-CT in detecting recurrent or metastatic lesions in patients with well-differentiated thyroid cancer who have elevated serum thyroglobulin level but negative 131I whole body scan. Methods: A retrospective study was performed in 23 patients with recurrent well-differentiated thyroid cancer who underwent FDG PET-CT in our institute from August 2003 to November 2006. All of these patients had received total thyroidectomy and 131I treatment, and subsequently presented with elevated serum thyroglobulin but negative 131I whole body scan. Among these 23 patients, 8 patients performed FDG PET-CT during high thyroid stimulating hormone (TSH) level and 15 patients performed FDG PET-CT during low TSH level. In all patients, results of FDG PET-CT were correlated with conventional images, histopathological findings and clinical follow-up. Results: FDG PET-CT showed positive findings in 17 of 23 patients, giving a sensitivity of 74%. There were altogether 25 metastatic lesions being detected in these 17 patients, which comprised of 14 neck lesions, 3 mediastinal lesions, 4 lung lesions, 3 bone lesions and 1 soft tissue lesion. FDG PET-CT led to a change in management in 8 patients, in whom 6 patients received surgery, 1 patient received radiation therapy of bone metastasis and the remaining patient received alcohol injection of metastatic neck lymph node. In 6 patients with negative finding on FDG PET-CT, 3 patients developed neck recurrence within 12 months after PET study. In our study, the sensitivity of FDG PET-CT was not improved by high serum TSH level. Conclusion: FDG PET-CT is a reliable method for detecting recurrence in patients with well-differentiated thyroid cancer with elevated serum thyroglobulin and negative 131I whole body scan. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。